|
1
|
Yi W, Peng J, Zhang Y, et al: Differential
protein expressions in breast cancer between drug sensitive tissues
and drug resistant tissues. Gland Surg. 2:62–68. 2013.PubMed/NCBI
|
|
2
|
Barrett SV: Breast cancer. J R Coll
Physicians Edinb. 40:335–338. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perez EA and Spano JP: Current and
emerging targeted therapies for metastatic breast cancer. Cancer.
118:3014–3025. 2012. View Article : Google Scholar
|
|
4
|
Satoda M, Takagi S, Ohta K, et al:
Differential expression of two cell surface proteins, neuropilin
and plexin, in Xenopus olfactory axon subclasses. J Neurosci.
15:942–955. 1995.PubMed/NCBI
|
|
5
|
Jubb AM, Strickland LA, Liu SD, et al:
Neuropilin-1 expression in cancer and development. J Pathol.
226:50–60. 2012. View Article : Google Scholar
|
|
6
|
Soker S, Takashima S, Miao HQ, Neufeld G
and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor
cells as an isoform-specific receptor for vascular endothelial
growth factor. Cell. 92:735–745. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miao HQ, Lee P, Lin H, Soker S and
Klgsbrun M: Neuropilin-1 expression by tumor cells promotes tumor
angiogenesis and progression. FASEB J. 14:2532–2539. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soker S, Takashima S, Miao HQ, et al:
Neuropilin-1 is expressed by endothelial and tumor cells as an
isoform-specific receptor for vascular endothelial growth factor.
Cell. 92:735–745. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guttmann-Raviv N, Kessler O, Shraga-Heled
N, et al: The neuropilins and their role in tumorigenesis and tumor
progression. Cancer Lett. 231:1–11. 2006. View Article : Google Scholar
|
|
10
|
Karjalainen K, Jaalouk DE, Bueso-Ramos CE,
et al: Targeting neuropilin-1 in human leukemia and lymphoma.
Blood. 117:920–927. 2011. View Article : Google Scholar
|
|
11
|
Pan Q, Chanthery Y, Liang WC, et al:
Blocking neuropilin-1 function has an additive effect with
anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53–67. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang ZL, Tang ZC, Zhang Y, et al:
Neuropilin-1 down-regulation impairs cell migration and induces the
differentiation of human tongue squamous cell carcinoma cells. Head
Neck Oncol. 4:542012.
|
|
13
|
Cao J, Meng FJ, Li L, et al: Expression of
NANOG gene in acute lymphoblastic leukemia cells and construction
of lentiviralvector carrying NANOG specific shRNA. Zhongguo Shi Yan
Xue Ye Xue Za Zhi. 22:275–279. 2014.In Chinese. PubMed/NCBI
|
|
14
|
Jha K, Shukla M and Pandey M: Survivin
expression and targeting in breast cancer. Surg Oncol. 21:125–131.
2012. View Article : Google Scholar
|
|
15
|
Alvarez RH, Valero V and Hortobagyi GN:
Emerging targeted therapies for breast cancer. J Clin Oncol.
28:3366–3379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koutras AK, Fountzilas G, Makatsoris T, et
al: Bevacizumab in the treatment of breast cancer. Cancer Treat
Rev. 36:75–82. 2010. View Article : Google Scholar
|
|
17
|
Goldfarb SB, Traina TA and Dickler MN:
Bevacizumab for advanced breast cancer. Womens Health (Lond Engl).
6:17–25. 2010. View Article : Google Scholar
|
|
18
|
Alvarez RH, Guarneri V, Icli F, et al:
Bevacizumab treatment for advanced breast cancer. Oncologist.
16:1684–1697. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miles DW, Chan A, Dirix LY, et al: Phase
III study of bevacizumab plus docetaxel compared with placebo plus
docetaxel for the first-line treatment of human epidermal growth
factor receptor 2-negative metastatic breast cancer. J Clin Oncol.
28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Robert NJ, Diéras V, Glaspy J, et al:
RIBBON-1: randomized, double-blind, placebo-controlled, phase III
trial of chemotherapy with or without bevacizumab for first-line
treatment of human epidermal growth factor receptor 2-negative,
locally recurrent or metastatic breast cancer. J Clin Oncol.
29:1252–1260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miller KD, Chap LI, Holmes FA, et al:
Randomized phase III trial of capecitabine compared with
bevacizumab plus capecitabine in patients with previously
treatedmetastatic breast cancer. J Clin Oncol. 23:792–799. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choueiri TK, Mayer EL, Je Y, et al:
Congestive heart failure risk inpatients with breast cancer treated
with bevacizumab. J Clin Oncol. 29:632–638. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghosh S, Sullivan CA, Zerkowski MP, et al:
High levels of vascular endothelial growth factor and its receptors
(VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome
in breast cancer. Hum Pathol. 39:1835–1843. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herzog Y, Kalcheim C, Kahane N, et al:
Differential expression of neuropilin-1 and neuropilin-2 in
arteries and veins. Mech. 109:115–119. 2001.
|
|
25
|
Yuan L, Moyon D, Pardanaud L, et al:
Abnormal lymphatic vessel development in neuropilin 2 mutant mice.
Development. 129:4797–4806. 2002.PubMed/NCBI
|
|
26
|
Ochiumi T, Kitadai Y, Tanaka S, et al:
Neuropilin-1 is involved in regulation of apoptosis and migration
of human colon cancer. Int J Oncol. 29:105–116. 2006.PubMed/NCBI
|
|
27
|
Li X, Tang T, Lu X, et al: RNA
interference targeting NRP-1 inhibits human glioma cell
proliferation and enhances cell apoptosis. Mol Med Rep.
4:1261–1266. 2011.PubMed/NCBI
|
